Myostatin, a transforming growth factor–β family member, is a negative regulator of skeletal
muscle growth. To explore the therapeutic potential of targeting myostatin in settings of …

Myostatin is a negative regulator of muscle growth. Loss of myostatin has been shown to
cause increase in skeletal muscle size and improve skeletal muscle function and fibrosis in …

Myostatin is an endogenous inhibitor of muscle conserved across diverse species. In the
absence of myostatin, there is massive muscle growth in mice, cattle, and humans. Previous …

Genetic deletion of Myostatin, a member of the Transforming Growth Factor-beta family of
signalling molecules, resulted in excessive growth of skeletal muscle. It demonstrated the …

Myostatin, a TGF-β family member, is a negative regulator of muscle growth. Here, we
generated transgenic mice that expressed myostatin mutated at its cleavage site under the …

A human therapeutic that specifically modulates skeletal muscle growth would potentially
provide a benefit for a variety of conditions including sarcopenia, cachexia, and muscular …

Myostatin is a negative regulator of skeletal muscle growth. Myostatin mutations and
pharmacological strategies increase muscle mass in vivo, suggesting that myostatin …

Myostatin is a secreted protein that negatively regulates skeletal muscle mass determining
both muscle fiber number and size. The myostatin pathway is conserved and regulates …

Increasing the size and strength of muscles represents a promising therapeutic strategy for
musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of …

Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …